Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $8.3750 (5.81%) ($8.3750 - $8.3750) on Tue. Mar. 8, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.26% (three month average) | RSI | 28 | Latest Price | $8.3750(5.81%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.5% a day on average for past five trading days. | Weekly Trend | FOLD declines -5.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(63%) IWO(52%) IWM(49%) IWC(48%) XBI(46%) | Factors Impacting FOLD price | FOLD will decline at least -2.13% in a week (0% probabilities). VIXM(-28%) VXX(-13%) UUP(-12%) UNG(-8%) EDOC(-8%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.13% (StdDev 4.26%) | Hourly BBV | 1.7 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-3.28(-139.16%) | Resistance Level | $8.62 | 5 Day Moving Average | $8.11(3.27%) | 10 Day Moving Average | $8.18(2.38%) | 20 Day Moving Average | $8.62(-2.84%) | To recent high | -32.8% | To recent low | 6.2% | Market Cap | $2.163b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |